Protocol Ledger

NCT04462770 · Phase III · RECRUITING

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Interventional Phase III clinical trial protocol NCT04462770 sponsored by Epygenix in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-15 Enrollment: 150 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04462770
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04462770
Protocol FieldVerified Registry Value
NCT IdentifierNCT04462770
Consolidated Lead SponsorEpygenix
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment150 participants (ESTIMATED)
Registered Start Date2020-09-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI